Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration

PURPOSE: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents such as brolucizumab and aflibercept are used widely to treat neovascular age-related macular degeneration (nAMD); however; they may theoretically affect the ocular blood flow. We investigated the short-term ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Nobuhiro, Haruta, Masatoshi, Furushima, Kei, Arai, Rikki, Matsuo, Yu, Yoshida, Shigeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122494/
https://www.ncbi.nlm.nih.gov/pubmed/37096209
http://dx.doi.org/10.2147/OPTH.S407249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122494/
https://www.ncbi.nlm.nih.gov/pubmed/37096209
http://dx.doi.org/10.2147/OPTH.S407249

Ejemplares similares